China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug

Jiangsu Hengrui Pharmaceuticals SSE:600276, China's largest drugmaker by market value, said on Tuesday it will license global rights to its weight-management drug HRS-1596 to Novo Nordisk A/S OMXCOP:NOVO_B in a deal worth up to $2.6 billion.Under the agreement, Novo Nordisk gains exclusive rights t…